Anavex Life Sciences Corp (AVXL)

[Investor2014]

There should be no doubt by now that the P2b/3 trial did not have data to support a traditional approval.

Hence AA is a potential backup for commercialisation along with the optimal strategy of Anavex in parallel with discussing AA pathways with regulatory authorities is planning to initiate a (P3) Confirmatory (Precision Medicine) trial (selecting only for responders to A2-73).

This will ensure Anavex will already be on the way towards hopefully gaining traditional approval with an appropriate label even if not granted AA.